Fig. 4: Activity of gemcitabine in an MBD4-deficient UM patient-derived xenograft (PDX) model and in the corresponding metastatic patient. | npj Precision Oncology

Fig. 4: Activity of gemcitabine in an MBD4-deficient UM patient-derived xenograft (PDX) model and in the corresponding metastatic patient.

From: Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency

Fig. 4: Activity of gemcitabine in an MBD4-deficient UM patient-derived xenograft (PDX) model and in the corresponding metastatic patient.The alternative text for this image may have been generated using AI.

A Schema of a co-clinical trial model between a PDX model and the patient from whom was derived the PDX. Created with BioRender.com. B Mice were treated with different drugs and tumor growth was assessed by measuring the relative tumor volume (RTV) for 32 days (n = 4 mice/drug, mean ± SD; n.s non-significant; **P < 0.01; unpaired two-sided Student’s t-test). C Positron emission tomography-computed tomography images before and after 5 months of dacarbazine (upper panel), and before and after 9 months of gemcitabine treatment (lower panel). Arrows show locations of metastatic lesions. D Evolution of the size of metastases during and after dacarbazine or gemcitabine treatment.

Back to article page